Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 1 histology subgroups

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorscopusidSaadettin Kılıçkap / 8665552100en_US
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021en_US
dc.contributor.authorSezer, A.
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorGümüş, M
dc.contributor.authorBondarenko, Igor
dc.contributor.authorÖzgüroğlu, Mustafa
dc.contributor.authorGogishvili, Miranda
dc.contributor.authorHe, X.
dc.contributor.authorGullo, Guiseppe
dc.contributor.authorRietschel, Petra
dc.contributor.authorQuek, Ruben
dc.date.accessioned2022-12-21T08:29:42Z
dc.date.available2022-12-21T08:29:42Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractPatient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroupsen_US
dc.identifier.citationSezer, A., Kilickap, S., Gumus, M., Bondarenko, I., Ozguroglu, M., Gogishvili, M., ... & Quek, R. (2022). 1183P Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups. Annals of Oncology, 33, S1089.en_US
dc.identifier.doi10.1016/j.annonc.2022.07.1306en_US
dc.identifier.endpageS1089en_US
dc.identifier.issn0923-7534en_US
dc.identifier.issn1569-8041en_US
dc.identifier.issue7en_US
dc.identifier.startpageS1089en_US
dc.identifier.urihttp://dx.doi.org/10.1016/j.annonc.2022.07.1306
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3758
dc.identifier.volume33en_US
dc.identifier.wosWOS:000866211601445en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherELSEVIERen_US
dc.relation.ispartofANNALS OF ONCOLOGYen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titlePatient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 1 histology subgroupsen_US
dc.typeOtheren_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1-s2.0-S092375342203157X-main (2).pdf
Boyut:
103.91 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu